Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Polycythemia Vera 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Carcinoma, Hepatocellular 6Thrombocythemia, Essential 5Neoplasms 3Melanoma 3Skin Neoplasms 2Philadelphia Chromosome 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Leukemia 2Hepatitis C, Chronic 2Carcinoma, Squamous Cell 2Brain Neoplasms 2Solid Cancers 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm, Residual 1Neoplasm of Uncertain Malignant Potential 1Liver Cirrhosis 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Influenza, Human 1Infections 1Hepatitis D 1Hepatitis C 1Hepatitis B, Chronic 1Hepatitis B 1Hemangiosarcoma 1

Interventions

Influenza Vaccines 16trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine 2Vaccines 2Oseltamivir 2FluMist 2Cyclophosphamide 2ziprasidone 1vaxigrip 1thymoglobulin 1peginterferon alfa-2a 1influvac 1fludarabine 1baloxavir 1Zolpidem 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Tobramycin 1Starch 1Spironolactone 1Sevelamer 1SARS-CoV-2 inactivated vaccines 1Rocuronium 1Rituximab 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nivolumab 1Nifedipine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Influenza, Human × peginterferon alfa-2a × Clear all
NCT00962715 2012-08-03

Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Influenza, Human, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡